ArticleArchives of medical science : AMS2026
Exploring the potential causal role of IgG N-glycosylation in urological cancers: a two-sample Mendelian randomization study using European ancestry datasets.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Urological cancers pose a significant global health burden. Alterations in immunoglobulin G(IgG) N-glycosylation are implicated in cancer pathogenesis, but their causal role remains unclear. This study aimed to explore the potential causal associations between 77 specific IgG N-glycan traits (IGPs) and the risks of bladder, kidney, and prostate cancer. Material and methods: We conducted a two-sample Mendelian randomization (MR) study using summary-level data. Genetic instruments for IGPs were obtained from a genome-wide association study (GWAS) of European descent. Outcome data were sourced from the FinnGen consortium. The inverse-variance weighted (IVW) method was the primary analysis, supplemented by multiple sensitivity analyses (MR-Egger, weighted median, MR-PRESSO, and MR-RAPS). The Steiger test was used to confirm causal direction. Results: After false discovery rate (FDR) correction, one association remained statistically significant. Using the IVW method, genetically predicted higher levels of IGP23 were significantly associated with a decreased risk of bladder cancer (OR = 0.78, Conclusions: Our study provides evidence supporting a potential causal association between the IgG N-glycan trait IGP23 and the risk of bladder cancer. Other nominal associations require further investigation. These findings highlight IGP23 as a candidate for future mechanistic and translational research in bladder cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.